The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas
Abstract
PURPOSE: To evaluate the efficacy and safety of tositumomab and iodine I 131 tositumomab (Bexxar; Corixa Corp, Seattle, WA, and GlaxoSmithKline, Philadelphia, PA) in patients with chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin’s lymphoma (NHL) and to compare its efficacy to the patients’ last qualifying chemotherapy (LQC) regimens. PATIENTS AND METHODS: Sixty patients who had been treated with at least two protocol-specified qualifying chemotherapy regimens and had not responded or progressed within 6 months after their LQC were treated with a single course of iodine I 131 tositumomab. RESULTS: Patients had received a median of four prior chemotherapy regimens. A partial or complete response (CR) was observed in 39 patients (65%) after iodine I 131 tositumomab, compared with 17 patients (28%) after their LQC (P < .001). The median duration of response (MDR) was 6.5 months after iodine I 131 tositumomab, compared with 3.4 months after the LQC (P < .001). Two patients (3%) had a CR after their LQC, compared with 12 (20%) after iodine I 131 tositumomab (P < .001). The MDR for CR was 6.1 months after the LQC and had not been reached with follow-up of more than 47 months after iodine I 131 tositumomab. An independent review panel verified that 32 (74%) of the 43 patients with nonequivalent durations of response (> 30 days difference) had a longer duration of response after iodine I 131 tositumomab (P < .001). Only one patient was hospitalized for neutropenic fever. Five patients (8%) developed human antimurine antibodies, and one (2%) developed an elevated TSH level after treatment. Myelodysplasia was diagnosed in four patients in follow-up. CONCLUSION: A single course of iodine I 131 tositumomab was significantly more efficacious than the LQC received by extensively pretreated patients with chemotherapy-refractory, low-grade, or transformed low-grade NHL and had an acceptable safety profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291402 · Cited by 4,949
Note on the Sampling Error of the Difference Between Correlated Proportions or Percentages
McNemar, Q. (1947) · Psychometrika · doi:10.1007/bf02295996 · Cited by 4,754
Statistical Models Based on Counting Processes
Bry, X., Andersen, P. K., Borgan, Ø., Gill, R. D., Keiding, N., & Borgan, O. (1997) · Population (French Edition) · doi:10.2307/1534625 · Cited by 2,884
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Contingency Tables Involving Small Numbers and the χ2 Test
Yates, F. (1934) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.2307/2983604 · Cited by 1,281
Salacinski, P. R. P., McLean, C., Sykes, J. E. C., Clement-Jones, V. V., & Lowry, P. J. (1981) · Analytical Biochemistry · doi:10.1016/0003-2697(81)90703-x · Cited by 1,129
The Natural History of Initially Untreated Low-Grade Non-Hodgkin's Lymphomas
Horning, S. J., & Rosenberg, S. A. (1984) · New England Journal of Medicine · doi:10.1056/nejm198412063112303 · Cited by 909
MIRD primer for absorbed dose calculations
LOEVINGER, R., Budinger, T. F., & Watson, E. E. (1988) · Medical Entomology and Zoology · Cited by 552
Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) Antibody
Kaminski, M. S., Zasadny, K. R., Francis, I. R., Milik, A. W., Ross, C. W., Moon, S. D., Crawford, S. M., Burgess, J. M., Petry, N. A., Butchko, G. M., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199308123290703 · Cited by 547
Self-citationKaminski, M. S., Estes, J., Zasadny, K. R., Francis, I. R., Ross, C. W., Tuck, M., Regan, D., Fisher, S., Gutierrez, J., Kroll, S., et al. (2000) · Blood · doi:10.1182/blood.v96.4.1259 · Cited by 525
Follicular lymphoma: prognostic factors for response and survival.
Gallagher, C. J., Gregory, W. M., Jones, A. E., Stansfeld, A. G., Richards, M. A., Dhaliwal, H. S., Malpas, J. S., & Lister, T. A. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.10.1470 · Cited by 425
Self-citationIodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma
Kaminski, M. S., Zasadny, K. R., Francis, I. R., Fenner, M. C., Ross, C. W., Milik, A. W., Estes, J., Tuck, M., Regan, D., Fisher, S., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.1974 · Cited by 396
Self-citationVose, J. M., Wahl, R. L., Saleh, M., Rohatiner, A. Z., Knox, S. J., Radford, J. A., Zelenetz, A. D., Tidmarsh, G. F., Stagg, R. J., & Kaminski, M. S. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1316 · Cited by 359
Self-citationJohnson, P. W., Rohatiner, A. Z., Whelan, J. S., Price, C. G., Love, S., Lim, J., Matthews, J., Norton, A. J., Amess, J. A., & Lister, T. A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.140 · Cited by 337
Self-citationHistologic progression in non-Hodgkin's lymphoma
Hubbard, S., Chabner, B., DeVita, V. J., Simon, R., Berard, C., Jones, R., Garvin, A., Canellos, G., Osborne, C., & Young, R. (1982) · Blood · doi:10.1182/blood.v59.2.258.258 · Cited by 227
Histologic conversion in the non-Hodgkin's lymphomas.
Acker, B., Hoppe, R. T., Colby, T. V., Cox, R. S., Kaplan, H. S., & Rosenberg, S. A. (1983) · Journal of Clinical Oncology · doi:10.1200/jco.1983.1.1.11 · Cited by 213
Therapy Related Leukemias: Susceptibility, Prevention and Treatment
Leone, G. G. M., Voso, M. T., Sica, S., Roberta Morosetti, A., & Pagano, L. (2001) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190109057981 · Cited by 132
Wahl, R. L., Kroll, S., & Zasadny, K. R. (1998) · PubMed · Cited by 115
Self-citationFollicular low‐grade non‐Hodgkin's lymphoma: Long‐term outcome with or without tumor progression
Ersbøll, J., Schultz, H. B., Pedersen-Bjergaard, J., et al. (1989) · European Journal Of Haematology · doi:10.1111/j.1600-0609.1989.tb01205.x · Cited by 84
Cited by
Ligand-targeted therapeutics in anticancer therapy
Allen, T. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc903 · Cited by 1,647
Armitage, J. O., Gascoyne, R. D., Lunning, M. A., & Cavalli, F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32407-2 · Cited by 1,176
Witzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C., Joyce, R., Pohlman, B. L., Bartlett, N. L., Wiseman, G. A., Padre, N., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.076 · Cited by 1,170
131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma
Kaminski, M. S., Tuck, M., Estes, J., Kolstad, A., Ross, C. W., Zasadny, K., Regan, D., Kison, P., Fisher, S., Kroll, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041511 · Cited by 716
Self-citationImmunogenicity of engineered antibodies
Hwang, W. Y. K., & Foote, J. (2005) · Methods · doi:10.1016/j.ymeth.2005.01.001 · Cited by 630
Metadata
- Authors
- Kaminski, M. S., Zelenetz, A. D., Press, O. W., Saleh, M., Leonard, J., Fehrenbacher, L., Lister, T. A., Stagg, R. J., Tidmarsh, G. F., Kroll, S., Wahl, R. L., Knox, S. J., & Vose, J. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-10-01
- Volume
- 19
- Issue
- 19
- Pages
- 3918-3928
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2256690185
- Cited by
- 584
- References
- 24
- FWCI
- 27.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.